(Q51332810)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Michel Dubar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Bernard Sébastien

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Christian Laveille

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

19 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Pharmacology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

267-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

27 February 2020

cites work

1 reference

Glycaemic control in type 2 diabetes: targets and new therapies

21 January 2018

1 reference

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes.

21 January 2018

1 reference

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

21 January 2018

1 reference

Mathematical models of diabetes progression

21 January 2018

1 reference

Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

21 January 2018

1 reference

A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes

21 January 2018

1 reference

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

21 January 2018

1 reference

Drug treatment effects on disease progression.

21 January 2018

1 reference

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

21 January 2018

1 reference

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

21 January 2018

1 reference

Recruitment to a clinical trial improves glycemic control in patients with diabetes.

21 January 2018

1 reference

Disease progression, drug action and Parkinson's disease: why time cannot be ignored

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

21 January 2018

1 reference

Deteriorating beta-cell function in type 2 diabetes: a long-term model

21 January 2018

1 reference

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

Epidemic obesity and type 2 diabetes in Asia

21 January 2018

1 reference

Model-based drug development

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24122776%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference